Drug Monitoring, Antipsychotics, with Confirmation, Urine
- Laboratory
- Quest Diagnostics
- Test code
- 94528
- Specimen
- Urine
- Fasting
- Not stated
- LOINC
- 12320-8, 14070-7, 19395-3, 19478-7, 19546-1, 19706-1, 20523-7, 20530-2, 20544-3, 20560-9, 21047-6, 29403-3, 32065-5, 32129-9, 3651-7, 3729-1, 40390-7, 42523-1, 59171-9, 59174-3, 60116-1, 77761-5, 77877-9, 77880-3, 77884-5, 77888-6, 77961-1, 78877-8, 78884-4, 89964-1, 89965-8, 89966-6, 89967-4, 89968-2, 89969-0, 89970-8, 89971-6, 89972-4, 89973-2, 89974-0, 89975-7, 89976-5, 89977-3, 89978-1, 90471-4, 98960-8, 98961-6, 98962-4, 98963-2, 98964-0, 98965-7
- Turnaround
- Set up: Tues, Thurs, Sat (10:00 a.m.); Report available: 1-4 days
Laboratory assay overview
Antipsychotic (AP) drugs are widely prescribed for the treatment of schizophrenia and psychosis. The so-called first generation or typical APs were developed in the 1950s and show severe side-effects such as extrapyramidal symptoms due to their pharmacological action on d2 and d4 receptors. As a measure of reducing these severe side-effects, a range of ‘second generation’ APs were developed. These newer generation drugs act considerably less on d2 and d4 receptors and therefore exhibit less extrapyramidal side-effects. Over the last decade, the prescription rate of APs (more notably second generation) has increased worldwide, [1-3] especially among young adults and children [1-4]. However, second generation APs are not entirely free of side-effects. Irrespective of their generation, it has been shown that these drugs can increase the risk of sudden cardiac death with studies showing that the risk of sudden cardiac death is increased threefold among patients treated with APs.
View complete laboratory reference notes
See Laboratory Report
Quest Diagnostics test directory, test code 94528